Lumosa announced today (2024/9/27) that its partner in China, Shanghai Pharmaceuticals, has notified the Company that the final patient follow-up has been completed in the Phase II clinical trial in China for LT3001, a novel treatment for acute ischemic stroke. All 300 subjects have completed the trial process, and full trial results are expected by the end of 2024.
This milestone marks a key step toward commercialization for LT3001. Compared to existing rt-PA thrombolytic agents, which only benefit 3-5% of patients and carry the risk of hemorrhage, LT3001 offers dual thrombolytic and neuroprotective functions and can be administered within a 24-hour therapeutic window, significantly expanding the applicable patient population.
There are approximately 15 million people worldwide suffer ischemic stroke annually, creating a significant unmet medical need. If LT3001 successfully overcomes the limitations of existing therapies, it could capture a potential market of up to US$10.6 billion, creating significant commercial value for Lumosa and solidifying its innovative leadership in the treatment of neurological diseases.